Posted by Michael Wonder on 25 Oct 2022
EndoStim receives FDA breakthrough device designation for the EndoStim system for the treatment of drug refractory GERD
25 October 2022 - EndoStim announced today that the US FDA granted breakthrough device designation for the Company’s EndoStim system.
The EndoStim system consists of an implantable neurostimulation device and lead placed via a quick, minimally invasive laparoscopic procedure.
